VXRT - Vaxart Inc
IEX Last Trade
0.8736
0.022 2.473%
Share volume: 1,600,564
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.85
0.02
2.54%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-08 | 2022-11-09 | 2023-03-15 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-03-14 | 2024-05-13 | |
Assets | |||||||||
Total Assets | 181.454 M | 175.309 M | 153.847 M | 129.851 M | 122.653 M | 105.642 M | 91.830 M | 88.670 M | |
Current Assets | 137.810 M | 120.380 M | 99.451 M | 75.830 M | 71.261 M | 57.100 M | 45.536 M | 44.284 M | |
Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Other Current Assets | 8.264 M | 5.613 M | 3.714 M | 3.755 M | 3.327 M | 3.639 M | 2.815 M | 6.924 M | |
Short Term Investments | 8.264 M | 5.613 M | 3.714 M | 3.755 M | 3.327 M | 3.639 M | 2.815 M | 6.924 M | |
Total Receivables | 0.000 | 0.000 | 20.000 K | 264.000 K | 29.000 K | 424.000 K | 3.008 M | 696.000 K | |
Current Cash | 129.546 M | 114.767 M | 93.717 M | 71.811 M | 67.905 M | 53.037 M | 39.713 M | 36.664 M | |
Total Non-current Assets | 43.644 M | 54.929 M | 54.396 M | 54.021 M | 51.392 M | 48.542 M | 46.294 M | 44.386 M | |
Property Plant Equipment | 9.336 M | 12.280 M | 15.585 M | 14.373 M | 13.918 M | 12.926 M | 11.731 M | 11.102 M | |
Other Assets | 5.478 M | 1.923 M | 3.568 M | 2.460 M | 1.508 M | 883.000 K | 926.000 K | 917.000 K | |
Intangible Assets | 9.949 M | 9.611 M | 5.020 M | 4.837 M | 4.654 M | 4.472 M | 4.289 M | 4.106 M | |
Goodwill | 4.508 M | 4.508 M | 4.508 M | 4.508 M | 4.508 M | 4.508 M | 4.508 M | 4.508 M | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 181.454 M | 175.309 M | 153.847 M | 129.851 M | 122.653 M | 105.642 M | 91.830 M | 88.670 M | |
Total liabilities | 38.360 M | 53.002 M | 43.250 M | 40.098 M | 37.580 M | 34.121 M | 34.025 M | 32.980 M | |
Total current liabilities | 15.926 M | 21.740 M | 17.921 M | 15.683 M | 13.883 M | 11.268 M | 13.724 M | 14.117 M | |
Accounts Payable | 5.007 M | 7.916 M | 5.514 M | 3.882 M | 4.199 M | 1.339 M | 1.584 M | 3.978 M | |
Other liabilities | 10.865 M | 11.243 M | 5.852 M | 5.243 M | 5.131 M | 4.911 M | 2.916 M | 2.172 M | |
Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Other liabilities | 10.865 M | 11.243 M | 5.852 M | 5.243 M | 5.131 M | 4.911 M | 2.916 M | 2.172 M | |
Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Total Shareholder equity | 143.094 M | 122.307 M | 110.597 M | 89.753 M | 85.073 M | 71.521 M | 57.805 M | 55.690 M | |
Common stock | 126.428 M | 126.890 M | 131.622 M | 135.213 M | 139.594 M | 152.026 M | 152.446 M | 168.811 M | |
Retained earnings | -273.882 M | -303.191 M | -327.109 M | -352.249 M | -374.799 M | -392.199 M | -409.574 M | -433.991 M |